Why Is 10x Genomics (TXG) Stock Down -13.52% Today?
Key Takeaways
- TXG shares fell roughly 13.5% in Monday's session, extending a sharp pullback after a multi-month rally that more than tripled the stock.
- The sell-off was driven primarily by valuation and "bubble" concerns after the stock's rapid run-up left it trading at elevated multiples relative to its still-negative earnings.
- A regulatory filing for a proposed share sale by an insider affiliate added to the selling pressure and chilled sentiment.
- Fundamental worries persisted around weaker instrument sales, the company's ongoing losses, and capacity bottlenecks for its new Atera platform.
- Traders are watching for further insider-selling disclosures, analyst commentary, and the company's next earnings report for signs of whether growth can justify the valuation.
Opening Summary
Shares of 10x Genomics, Inc. (TXG), a life science technology company that develops instruments, consumables, and software for single-cell and spatial biology, tumbled sharply on Monday. The stock fell about 13.5% to roughly $84.53, down from a prior closing price of $97.74. The decline marked a decisive reversal for a name that had been one of the market's hottest momentum stories, as investors reassessed a valuation that had surged well ahead of the company's underlying financial performance.
Bubble Fears and a Valuation Reassessment
The central catalyst behind Monday's move was a broad reassessment of TXG's valuation. After tripling in roughly six months and climbing hundreds of percent year-to-date, the stock began to look stretched on traditional metrics. Analysts flagged bubble-like conditions, pointing to a forward price-to-earnings ratio that had surged to levels difficult to justify against the company's current earnings, which remain negative. With the shares trading at a steep premium to the company's fundamentals, profit-taking and de-risking accelerated once momentum stalled, triggering a sharp, high-volume sell-off.
Insider Share-Sale Filing Chills Sentiment
Adding to the pressure, a regulatory filing disclosed a proposed sale of securities by an affiliate of the company under Rule 144. Insider selling can unsettle investors in a richly valued stock, as it is often read as a signal that those closest to the business are taking advantage of elevated prices. Recent months have seen a series of insider transactions and Rule 144 filings tied to 10x Genomics leadership, and the latest disclosure reinforced the perception that insiders were capitalizing on the stock's dramatic run, further eroding confidence among holders.
Fundamental Concerns Persist
Beneath the valuation debate, investors continued to weigh the company's fundamentals. 10x Genomics remains unprofitable on a net basis and has been contending with weaker instrument sales as customers moderate purchases of existing spatial products ahead of the transition to its new Atera platform. Management has acknowledged that Atera shipments are limited by manufacturing ramp-up rather than demand, leaving near-term revenue growth vulnerable to execution wobbles. While the company's consumables business provides steady, repeat revenue, the combination of losses, instrument headwinds, and capacity bottlenecks left little fundamental cushion to support the stock's elevated price.
Market Context and Trading Activity
Monday's decline unfolded on elevated volume, consistent with a momentum unwind rather than an isolated, low-liquidity move. The pullback stood in contrast to the broader market and diverged from the prior sector strength that had carried TXG higher for much of the year. Technical support levels that had held during the rally gave way as selling cascaded, underscoring how quickly a crowded, high-momentum trade can reverse. The stock's extreme volatility — it has registered dozens of moves greater than 5% over the past year — amplified the session's losses.
What Comes Next for TXG
Looking ahead, investors will be closely watching whether the selling stabilizes or extends, as well as any additional insider-sale disclosures that could signal further supply of shares. The company's next earnings report will be a key test, particularly for updates on Atera shipments, consumables growth, and whether revenue can reaccelerate enough to support the valuation. Analyst commentary and any adjustments to price targets could also influence sentiment. Key risks include continued weakness in instrument sales, execution challenges in scaling Atera production, and the broader risk that a sustained market rotation away from high-momentum, richly valued growth names keeps pressure on the stock.
Trending AI Robots
For traders looking to navigate volatile names like TXG, Tickeron offers hundreds of AI-powered trading bots that monitor thousands of tickers around the clock. Only the strongest performers under current market conditions are featured in the curated Trending AI Robots section. These bots vary by strategy, timeframe, performance metrics, and traded symbols, allowing users to explore automated approaches suited to different market environments. Discover the bots currently leading the market today.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Financial analyst and market blogger with expertise in equity research, fundamental analysis, and macroeconomic trends. I regularly publish coverage on individual stocks, ETFs, and sector developments — combining rigorous financial analysis with clear, engaging writing for a broad investment audience.
Momentum Indicator for TXG turns positive, indicating new upward trend
TXG saw its Momentum Indicator move above the 0 level on September 08, 2026. This is an indication that the stock could be shifting in to a new upward move. Traders may want to consider buying the stock or buying call options. Tickeron's A.I.dvisor looked at 85 similar instances where the indicator turned positive. In 70 of the 85 cases, the stock moved higher in the following days. The odds of a move higher are at 82%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Moving Average Convergence Divergence (MACD) for TXG just turned positive on September 14, 2026. Looking at past instances where TXG's MACD turned positive, the stock continued to rise in 36 of 45 cases over the following month. The odds of a continued upward trend are 80%.
Following a +10.12% 3-day Advance, the price is estimated to grow further. Considering data from situations where TXG advanced for three days, in 209 of 269 cases, the price rose further within the following month. The odds of a continued upward trend are 78%.
The Aroon Indicator entered an Uptrend today. In 191 of 232 cases where TXG Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 82%.
Bearish Trend Analysis
The RSI Indicator demonstrates that the ticker has stayed in the overbought zone for 7 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 18 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
TXG broke above its upper Bollinger Band on September 17, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Fundamental Analysis (Ratings)
The Tickeron Price Growth Rating for this company is 34 (best 1 - 100 worst), indicating steady price growth. TXG’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 44 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (13.966) is normal, around the industry mean (10.853). P/E Ratio (0.000) is within average values for comparable stocks, (98.910). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (11.052). Dividend Yield (0.000) settles around the average of (0.002) among similar stocks. P/S Ratio (15.038) is also within normal values, averaging (39.828).
The Tickeron SMR rating for this company is 93 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron PE Growth Rating for this company is 100 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. TXG’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 96, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a life science technology company, which engages in building products to interrogate, understand and master biology
Industry MedicalNursingServices
Advertisement